SecBot SecBot

NBP

NovaBridge Biosciences
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001778016 Biotech & Drug Discovery
$1.22 −0.15 (−11.31%)
Oct 26 4:00 PM ET · prev $1.37
Market cap
$153.5M
Micro cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
$9.00
+641% · range $9.00–9.00
1 year
−74.1%
from $4.70 · Oct 27
30 days
−10.7%
from $1.36
52-week range
$1.22–4.95
at the low
Avg volume 20D
424.7K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$423.0K
1 buyer · 3 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 2 bearish · 3 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/9
Strongest BULLISH NovaBridge presented updated Phase 1b data for givastomig at ESMO 2026, showing an 79% objective response…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $577.3K at an average $2.51. 3 insiders sold $154.3K. Price is 52% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 6 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    23% below its 50-day average. New closing low $1.22 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCDOUBLED758,226$1.5M
CITADEL ADVISORS LLCDOUBLED622,831$1.2M
Woodline Partners LPTRIM350,000$682.5K
UBS Group AGDOUBLED301,780$588.5K
GOLDMAN SACHS GROUP INCADD161,321$314.6K
JPMORGAN CHASE & COADD81,556$161.5K
BNP PARIBAS FINANCIAL MARKETSTRIM28,836$56.2K
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED28,539$55.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy2Buy4Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +641%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 20, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$577.3K
bought · 1 insider
$154.3K
sold · 3 insiders
−51.6%
vs their $2.51 cost
DateInsiderTypeValue
Oct 15, 2026
Woo Ian Ying
Director
EXERCISE13,271 sh
Oct 15, 2026
Woo Ian Ying
Director
EXERCISE5,770 sh
Sep 18, 2026
Dennis Phillip Andrew
Chief Medical Officer
SELL$5.8K
Sep 17, 2026
Dennis Phillip Andrew
Chief Medical Officer
EXERCISE10,302 sh
Sep 17, 2026
Dennis Phillip Andrew
Chief Medical Officer
EXERCISE23,695 sh
Sep 9, 2026
Cao Sean Wuxiong
Chief Bus. Development Officer
SELL$79.9K
Sep 3, 2026
Cao Sean Wuxiong
Chief Bus. Development Officer
EXERCISE45,320 sh
Sep 3, 2026
Cao Sean Wuxiong
Chief Bus. Development Officer
EXERCISE102,233 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$0.91-$0.91–-$0.91+3.2%$0.00
Next FY-$0.63-$0.63–-$0.63+40.6%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 25, 2026 Press
NovaBridge presented updated Phase 1b data for givastomig at ESMO 2026, showing an 79% objective response rate and…
Impact 7/10
Oct 25, 2026 FDA
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen th
Oct 23, 2026 SEC
NovaBridge Biosciences reported that clinical data from the ongoing Phase 1 trial of ragistomig (ABL503/TJ-L14B), a…
6-K — Impact 3/10
Oct 15, 2026 Insider
Woo Ian Ying acquired via exercise 13,271 shares
Director
Oct 15, 2026 Insider
Woo Ian Ying acquired via exercise 5,770 shares
Director
Oct 13, 2026 SEC
NovaBridge's majority-owned ophthalmology subsidiary Visara in-licensed VIS-102 (HT006.2.2), a modified recombinant…
6-K — Impact 5/10
Sep 18, 2026 Insider
Dennis Phillip Andrew sold 8,209 shares
Chief Medical Officer @ $0.7100 ($5.8K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 25, 2026
FDA
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in…
Oct 15, 2026
Short interest
🔒 Fresh data, subscribers only
Oct 13, 2026
Press release
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), exclusive worldwide rights, excluding…
Sep 8, 2026
Press release
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology…
Aug 31, 2026
Short interest
Short Interest: NBP down 22% to 3.6M shares
Settlement 2026-08-31 | Days to cover: 12.22 | ≈3.11% of shares outstanding (est.)

SecBot reports

17 filings · 3 press releases · 6 bullish · 2 bearish · 9 neutral
All NBP filing & press-release reports (20)